ncidence rates of inflammatory bowel disease (IBD) among patients being treated with secukinumab (Cosentyx) for rheumatic inflammatory diseases were low, pooled clinical trial data indicated.
ncidence rates of inflammatory bowel disease (IBD) among patients being treated with secukinumab (Cosentyx) for rheumatic inflammatory diseases were low, pooled clinical trial data indicated.